Investigational Drug Details
| Drug ID: | D116 |
| Drug Name: | Dulaglutide |
| Synonyms: | LY2189265 |
| Type: | Biological drug |
| DrugBank ID: | DB09045 |
| DrugBank Description: | Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA in 2014, and in February 2020 was approved for use in patients with T2DM and multiple cardiovascular risk factors for the prevention of cardiovascular events. It is the first T2DM drug approved to reduce major adverse cardiovascular events (MACE) risk in primary and secondary prevention populations. |
| PubChem ID: | -- |
| CasNo: | 923950-08-7 |
| Repositioning for NAFLD: | Yes |
| SMILES: | -- |
| InChiKey: | -- |
| Molecular Weight: | -- |
| DrugBank Targets: | Glucagon-like peptide 1 receptor agonist |
| DrugBank MoA: | Dulaglutide activates the GLP-1 receptor found in pancreatic beta cells, increasing intracellular cyclic AMP (cAMP) in beta cells, leading to insulin release and subsequent reduction of blood glucose concentrations. Additionally, dulaglutide decreases glucagon secretion and slows gastric emptying. |
| DrugBank Pharmacology: | Dulaglutide reduces fasting glucose concentrations and reduces postprandial glucose (PPG) concentrations in patients with type 2 diabetes mellitus through the agonism of the GLP-1 receptor. This drug primarily acts as an incretin mimetic hormone or analog of human glucagon-like peptide-1, which normally acts on the GLP-1 receptor. |
| DrugBank Indication: | Dulaglutide is as an adjunct therapy to diet and exercise for glycemic control in adults with type 2 diabetes mellitus. Additionally, it is indicated to reduce the risk of major adverse cardiovascular events (MACE) in adult type 2 diabetes mellitus patients with cardiovascular disease or multiple cardiovascular risk factors. |
| Targets: | GLP1R agonist |
| Therapeutic Category: | Improve insulin resistance |
| Clinical Trial Progress: | Clinical trial completed (NCT03590626: When included in the standard treatment for type 2 diabetes, dulaglutide significantly reduces LFC and improves GGT levels in participants with NAFLD. There were non-significant reductions in PFC, liver stiffness, serum AST and serum ALT levels. Dulaglutide could be considered for the early treatment of NAFLD in patients with type 2 diabetes.) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0048 | NCT03590626 | Not applicable | Completed | No Results Available | January 1, 2019 | February 20, 2020 | Details |
| L0703 | KCT0004923 | Not applicable | Recruiting | No Results Available | 16/04/2020 | 21 April 2020 | Details |
| L0789 | NCT03648554 | Phase 4 | Not recruiting | No Results Available | 27/07/2018 | 12 December 2020 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S08 | Lifestyle measures | Lifestyle intervention; weight loss; diet adaptation; dietary interventions; lifestyle modifications; Exercise | -- | -- | Details |
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00303 | 35144334 | Endocrinol Metab (Seoul) | Dulaglutide Ameliorates Palmitic Acid-Induced Hepatic Steatosis by Activating FAM3A Signaling Pathway. | Details |
| A04758 | 33513761 | Metabolites | Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials. | Details |
| A04924 | 33447122 | Clin Med Insights Endocrinol Diabetes | Oral GLP1 Analog: Where Does the Tide Go? | Details |
| A06475 | 32865597 | Diabetologia | Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial). | Details |
| A07979 | 32291277 | Diabetes Care | Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes. | Details |
| A13622 | 29869810 | Diabet Med | Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme. | Details |
| A17198 | 27917557 | Hepatol Res | Effect of 12-week dulaglutide therapy in Japanese patients with biopsy-proven non-alcoholic fatty liver disease and type 2 diabetes mellitus. | Details |
| A29606 | 33808404 | Biomedicines | Dulaglutide Alone and in Combination with Empagliflozin Attenuate Inflammatory Pathways and Microbiome Dysbiosis in a Non-Diabetic Mouse Model of NASH. | Details |
| A50745 | 35280867 | Front Med (Lausanne) | Efficacy of Off-Label Therapy for Non-alcoholic Fatty Liver Disease in Improving Non-invasive and Invasive Biomarkers: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. | Details |